Biomarker
Galectin-3
Gal-3 — Galectin-3 is a beta-galactoside-binding lectin that plays a central role in fibrosis, inflammation, and tissue remodeling across multiple organ systems. In cardiology, elevated galectin-3 levels are associated with myocardial fibrosis and adverse outcomes in heart failure, positioning it as a prognostic biomarker that captures the structural remodeling component of cardiac disease.
Overview
What is galectin-3?
Galectin-3 is a member of the galectin family of carbohydrate-binding proteins, characterized by its affinity for beta-galactoside sugars. It is expressed by macrophages, fibroblasts, and epithelial cells and participates in numerous biological processes including cell adhesion, proliferation, apoptosis, and immune regulation. In the context of tissue injury, activated macrophages secrete galectin-3, which promotes the proliferation and activation of fibroblasts, leading to collagen deposition and organ fibrosis. This pro-fibrotic cascade is particularly well-characterized in the heart, liver, and kidneys.
In heart failure, galectin-3 provides information that is fundamentally different from natriuretic peptides (like NT-proBNP) and troponin. While NT-proBNP reflects hemodynamic stress and troponin reflects acute myocardial injury, galectin-3 reflects the chronic structural remodeling process — the gradual replacement of functional heart muscle with fibrotic scar tissue. This fibrotic remodeling contributes to the progressive stiffening and dysfunction of the heart that characterizes both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
The FDA cleared a galectin-3 blood test in 2010 for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Galectin-3 levels above 17.8 ng/mL are associated with significantly higher risk of hospitalization and death. Unlike NT-proBNP, galectin-3 levels tend to change slowly over time, reflecting the gradual nature of the fibrotic process rather than acute hemodynamic fluctuations, making it a marker of disease trajectory rather than immediate clinical status.
Clinical Significance
Why galectin-3 matters in cardiac and fibrotic disease.
Heart failure prognostication. Elevated galectin-3 is independently associated with increased risk of mortality, hospitalization, and adverse cardiac events in chronic heart failure patients. It provides prognostic information beyond what NT-proBNP alone offers, particularly in heart failure with preserved ejection fraction where natriuretic peptide levels may be only modestly elevated.
Cardiac fibrosis assessment. Because galectin-3 is mechanistically linked to the fibrotic process itself — not just a correlate of disease severity — it provides direct biological insight into whether active cardiac remodeling is occurring. Cardiac MRI studies have confirmed correlations between circulating galectin-3 levels and the extent of myocardial fibrosis measured by late gadolinium enhancement.
Multi-organ fibrosis indicator. Galectin-3 is not heart-specific. Elevated levels have been associated with liver fibrosis, renal fibrosis, and pulmonary fibrosis. In patients with cardiac disease, concurrent elevation may reflect fibrotic processes occurring in multiple organ systems simultaneously, which has implications for overall disease burden assessment.
Therapeutic target research. Galectin-3 inhibitors are under investigation as potential anti-fibrotic therapies. If such therapies prove effective, galectin-3 levels could serve as both a biomarker for patient selection and a pharmacodynamic marker for monitoring treatment response, connecting diagnostic and therapeutic applications.
Prevena's Approach
Investigating continuous galectin-3 monitoring for fibrosis tracking.
Prevena Health is exploring whether continuous galectin-3 monitoring may support earlier detection of accelerating fibrotic remodeling in heart failure patients. Because galectin-3 levels change gradually, reflecting a slowly evolving biological process, periodic blood draws may miss subtle upward trends that signal a shift from stable to progressive disease. Continuous surveillance aims to detect these inflection points with greater temporal precision, potentially informing earlier therapeutic adjustments.
This approach may be particularly valuable when galectin-3 is tracked alongside hemodynamic markers like NT-proBNP and injury markers like troponin. The combination of three fundamentally different biological signals — fibrosis, wall stress, and cellular damage — monitored continuously through a single wearable platform, may provide a more comprehensive and nuanced picture of cardiac disease trajectory than any single biomarker measured at discrete time points. Prevena is investigating this multi-analyte approach as part of its broader cardiac biomarker research program.
Related Disease Areas
Conditions associated with galectin-3 research.
Related Biomarkers
Other biomarkers in this research area.
NT-proBNP
The primary hemodynamic stress biomarker in heart failure, providing complementary information to galectin-3's fibrosis signal.
High-Sensitivity Troponin
Reflects acute myocardial injury, adding a tissue damage dimension to galectin-3's chronic fibrosis assessment.
CRP
An inflammatory marker that, combined with galectin-3, may help distinguish inflammatory from purely fibrotic disease processes.
Prevena Health's platform is in development and is not commercially available. It has not been cleared, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. It is not a diagnostic device. Content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment.
Partner with us on cardiac fibrosis biomarker research.
We are seeking clinical and research collaborators to explore continuous fibrosis biomarker monitoring for heart failure research.
Partner With Us